Menu Back toMedical Approach in Diagnosis and Management of Adverse Drug Reactions (ADRs)

Medical Approach in Diagnosis and Management of Adverse Drug Reactions (ADRs)

Considered by many experts as one of the pillars of medical training in PhV, this course focuses on how to use medical knowledge in the diagnosis and management of selected ADRs.


Overview

The 26th edition of this training course, considered by many experts as one of the pillars of medical training in pharmacovigilance, focuses on how to use medical knowledge in the diagnosis and management of selected Adverse Drug Reactions (ADRs). ADRs of the main systems/organs will be presented and explained by experts in order to provide practical clues to understand and manage the serious reactions in clinical trials a well as in post authorisation.

A medical approach is needed for the identification, labelling and understanding of ADR mechanisms. It can also help assess the probability that a medicinal product may have played a role in the occurrence of an adverse event. This is particularly useful for the first 2 or 3 cases of serious reactions occurring during clinical trials when important decisions must be taken regarding a new drug under development.

The medical approach presented in this training course will take into consideration the conclusions of international or national consensus meetings on adverse drug reactions.

What participants from previous course say:

"A good overview of major organ involvement - each topic could easily fill a full day in the programme. Enjoyed the concepts presented in the affective symptoms session."

"The courses were very useful for me, and the materials are very clear with a good documentation."

"Dr Gaby Danan is a medical doctor that not only has a great knowledge in the field he works, but also is an excellent presenter, he knows how to keep the audience engaged. He not only explains the theoretical part, but also gives practical examples."

Who should attend?

All healthcare professionals involved in the monitoring and assessment of adverse drug reactions occurred in drug development or after marketing; EU–QPPV, staff in charge of pharmacovigilance and/or drug safety investigators, staff in charge of clinical trials and safety studies, clinical research associates and monitors.

Learning objectives

At the conclusion of this training course participants will be able to:

  • Classify and define drug-induced affective symptoms, skin reactions, QT interval prolongation, blood disorders, drug-induced liver injury (DILI), and acute renal failure
  • Describe their clinical patterns and appropriate investigations
  • Discuss the main non drug causes of the described disorders
  • Understand how to approach causality assessment in DILI

Participants will complete a knowledge check at the end of the course and will be provided with feedback to ensure learning objectives are attained.


Plan Your Team's Professional Development

Why not take advantage and train your whole department (or even across different departments!) and benefit from increased:

  • Focus
  • Flexibility
  • Convenience
  • Cost Effectiveness

For more information please contact EMEA@DIAglobal.org

Program Committee

  • Gaby L. Danan, MD, PhD
    Gaby L. Danan, MD, PhD Pharmacovigilance Expert
    France
Load More

Contact us



Registration Questions

Send Email
+41 61 225 51 51


Agenda and Logistics

Send Email
+41 61 225 51 55